Pfizer Inc. (PFE.F)
| Previous close | 23.68 |
| Open | 24.41 |
| Bid | 23.81 x 150000 |
| Ask | 23.84 x 150000 |
| Day's range | 23.57 - 23.83 |
| 52-week range | 23.57 - 37.45 |
| Volume | |
| Avg. volume | 8,870 |
| Market cap | 134.825B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 68.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.57 (6.63%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Business Wire
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
NEW YORK, April 26, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var)
- Business Wire
Pfizer Declares Second-Quarter 2024 Dividend
NEW YORK, April 24, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.
- Business Wire
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK, April 22, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative
